Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients with Chronic Liver Disease in Clinical Practice
Chronic liver disease results in a low response rate to the hepatitis B virus vaccine. Information on the efficacy of the double adjuvanted vaccine FENDRIX<sup>®</sup> (3-O-desacyl-4’-monophosphoryl lipid A and aluminum phosphate) and single adjuvant HBVAXPRO<sup>®</sup>40 (a...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/10/8/1323 |
| _version_ | 1797407537964777472 |
|---|---|
| author | Diana Horta Montserrat Forné Anna Agustí Agnes Raga Albert Martín-Cardona Juana María Hernández-Soto Pablo Ruiz-Ramírez Maria Esteve-Comas |
| author_facet | Diana Horta Montserrat Forné Anna Agustí Agnes Raga Albert Martín-Cardona Juana María Hernández-Soto Pablo Ruiz-Ramírez Maria Esteve-Comas |
| author_sort | Diana Horta |
| collection | DOAJ |
| description | Chronic liver disease results in a low response rate to the hepatitis B virus vaccine. Information on the efficacy of the double adjuvanted vaccine FENDRIX<sup>®</sup> (3-O-desacyl-4’-monophosphoryl lipid A and aluminum phosphate) and single adjuvant HBVAXPRO<sup>®</sup>40 (aluminum hydroxyphosphate sulfate) in chronic liver disease is scarce. The primary aim of this prospective study in clinical practice was to evaluate the effectiveness of HBVAXPRO<sup>®</sup>40 and FENDRIX<sup>®</sup> in this setting. Patients received HBVAXPRO<sup>®</sup> (0, 1 and 6 months) or FENDRIX<sup>®</sup> (0, 1, 2 and 6 months) depending on availability. Clinical data and anti-HBs levels were collected at 2, 6 and 12 months. A total of 125 patients were included (mean age 61.8 years; 57.6% males; 43.2% liver cirrhosis; 75.9% Child A and 24.1% Child B): 76 were vaccinated with HBVAXPRO<sup>®</sup> and 49 with FENDRIX<sup>®</sup>. There were no significant differences between the two vaccines. The overall response rates at 2, 6 and 12 months were 76.8, 72.8 and 59.2%, respectively. In the univariate analysis, active alcohol intake, alcohol etiology, liver cirrhosis and ultrasound signs of portal hypertension were associated with a lower response to vaccination, whereas in the multivariate analysis, liver cirrhosis was the only factor that significantly increased the likelihood of nonresponse (OR 10.5). HBVAXPRO<sup>®</sup> and FENDRIX<sup>®</sup> are good options for HBV vaccination in patients with chronic liver disease. |
| first_indexed | 2024-03-09T03:43:57Z |
| format | Article |
| id | doaj.art-f1284a71ab804334b2b2365cb0964c90 |
| institution | Directory Open Access Journal |
| issn | 2076-393X |
| language | English |
| last_indexed | 2024-03-09T03:43:57Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj.art-f1284a71ab804334b2b2365cb0964c902023-12-03T14:37:43ZengMDPI AGVaccines2076-393X2022-08-01108132310.3390/vaccines10081323Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients with Chronic Liver Disease in Clinical PracticeDiana Horta0Montserrat Forné1Anna Agustí2Agnes Raga3Albert Martín-Cardona4Juana María Hernández-Soto5Pablo Ruiz-Ramírez6Maria Esteve-Comas7Department of Gastroenterology and Hepatology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, 08221 Terrassa, SpainDepartment of Gastroenterology and Hepatology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, 08221 Terrassa, SpainDepartment of Gastroenterology and Hepatology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, 08221 Terrassa, SpainDepartment of Gastroenterology and Hepatology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, 08221 Terrassa, SpainDepartment of Gastroenterology and Hepatology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, 08221 Terrassa, SpainDepartment of Gastroenterology and Hepatology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, 08221 Terrassa, SpainDepartment of Gastroenterology and Hepatology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, 08221 Terrassa, SpainDepartment of Gastroenterology and Hepatology, Hospital Universitari Mútua Terrassa, Universitat de Barcelona, 08221 Terrassa, SpainChronic liver disease results in a low response rate to the hepatitis B virus vaccine. Information on the efficacy of the double adjuvanted vaccine FENDRIX<sup>®</sup> (3-O-desacyl-4’-monophosphoryl lipid A and aluminum phosphate) and single adjuvant HBVAXPRO<sup>®</sup>40 (aluminum hydroxyphosphate sulfate) in chronic liver disease is scarce. The primary aim of this prospective study in clinical practice was to evaluate the effectiveness of HBVAXPRO<sup>®</sup>40 and FENDRIX<sup>®</sup> in this setting. Patients received HBVAXPRO<sup>®</sup> (0, 1 and 6 months) or FENDRIX<sup>®</sup> (0, 1, 2 and 6 months) depending on availability. Clinical data and anti-HBs levels were collected at 2, 6 and 12 months. A total of 125 patients were included (mean age 61.8 years; 57.6% males; 43.2% liver cirrhosis; 75.9% Child A and 24.1% Child B): 76 were vaccinated with HBVAXPRO<sup>®</sup> and 49 with FENDRIX<sup>®</sup>. There were no significant differences between the two vaccines. The overall response rates at 2, 6 and 12 months were 76.8, 72.8 and 59.2%, respectively. In the univariate analysis, active alcohol intake, alcohol etiology, liver cirrhosis and ultrasound signs of portal hypertension were associated with a lower response to vaccination, whereas in the multivariate analysis, liver cirrhosis was the only factor that significantly increased the likelihood of nonresponse (OR 10.5). HBVAXPRO<sup>®</sup> and FENDRIX<sup>®</sup> are good options for HBV vaccination in patients with chronic liver disease.https://www.mdpi.com/2076-393X/10/8/1323vaccinationhepatitis B vaccinationhepatitis Bchronic liver diseaseliver cirrhosis |
| spellingShingle | Diana Horta Montserrat Forné Anna Agustí Agnes Raga Albert Martín-Cardona Juana María Hernández-Soto Pablo Ruiz-Ramírez Maria Esteve-Comas Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients with Chronic Liver Disease in Clinical Practice Vaccines vaccination hepatitis B vaccination hepatitis B chronic liver disease liver cirrhosis |
| title | Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients with Chronic Liver Disease in Clinical Practice |
| title_full | Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients with Chronic Liver Disease in Clinical Practice |
| title_fullStr | Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients with Chronic Liver Disease in Clinical Practice |
| title_full_unstemmed | Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients with Chronic Liver Disease in Clinical Practice |
| title_short | Efficacy of Hepatitis B Virus Vaccines HBVaxpro40© and Fendrix© in Patients with Chronic Liver Disease in Clinical Practice |
| title_sort | efficacy of hepatitis b virus vaccines hbvaxpro40 c and fendrix c in patients with chronic liver disease in clinical practice |
| topic | vaccination hepatitis B vaccination hepatitis B chronic liver disease liver cirrhosis |
| url | https://www.mdpi.com/2076-393X/10/8/1323 |
| work_keys_str_mv | AT dianahorta efficacyofhepatitisbvirusvaccineshbvaxpro40andfendrixinpatientswithchronicliverdiseaseinclinicalpractice AT montserratforne efficacyofhepatitisbvirusvaccineshbvaxpro40andfendrixinpatientswithchronicliverdiseaseinclinicalpractice AT annaagusti efficacyofhepatitisbvirusvaccineshbvaxpro40andfendrixinpatientswithchronicliverdiseaseinclinicalpractice AT agnesraga efficacyofhepatitisbvirusvaccineshbvaxpro40andfendrixinpatientswithchronicliverdiseaseinclinicalpractice AT albertmartincardona efficacyofhepatitisbvirusvaccineshbvaxpro40andfendrixinpatientswithchronicliverdiseaseinclinicalpractice AT juanamariahernandezsoto efficacyofhepatitisbvirusvaccineshbvaxpro40andfendrixinpatientswithchronicliverdiseaseinclinicalpractice AT pabloruizramirez efficacyofhepatitisbvirusvaccineshbvaxpro40andfendrixinpatientswithchronicliverdiseaseinclinicalpractice AT mariaestevecomas efficacyofhepatitisbvirusvaccineshbvaxpro40andfendrixinpatientswithchronicliverdiseaseinclinicalpractice |